INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors

Lisa M. Rooper, Justin A. Bishop, William H. Westra

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. We performed INSM1 immunohistochemistry on NE tumors (n=97) and non-NE tumors (n=626) across all histologic grades and anatomic subsites of the head and neck. INSM1 was positive in all types of head and neck NE tumors evaluated here (99.0% sensitivity), including middle ear adenoma, pituitary adenoma, paraganglioma, medullary thyroid carcinoma, olfactory neuroblastoma, small cell carcinoma, large cell NE carcinoma, and sinonasal teratocarcinosarcoma. Notably, it was positive in the vast majority of high-grade NE malignancies (95.8% sensitivity). INSM1 also was negative in almost all non-NE tumors (97.6% specificity) with the highest rates of reactivity in alveolar rhabdomyosarcoma and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (SMARCB1)-deficient sinonasal carcinoma. These findings confirm that INSM1 may be used as a standalone first-line marker of NE differentiation for tumors of the head and neck.

Original languageEnglish (US)
Pages (from-to)665-671
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume42
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Insulinoma
Differentiation Antigens
Neuroendocrine Tumors
Neck
Head
Neoplasms
Proteins
Alveolar Rhabdomyosarcoma
Olfactory Esthesioneuroblastoma
Chromogranins
Neuroendocrine Carcinoma
Large Cell Carcinoma
Paraganglioma
Synaptophysin
Small Cell Carcinoma
Pituitary Neoplasms
Middle Ear
Adenoma
Chromatin
Actins

Keywords

  • head and neck tumors
  • immunohistochemistry
  • INSM1
  • neuroendocrine tumors
  • surgical pathology

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors. / Rooper, Lisa M.; Bishop, Justin A.; Westra, William H.

In: American Journal of Surgical Pathology, Vol. 42, No. 5, 01.01.2018, p. 665-671.

Research output: Contribution to journalArticle

@article{ff1e68bb3e0d4dc284d0f03136a6ad3e,
title = "INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors",
abstract = "The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. We performed INSM1 immunohistochemistry on NE tumors (n=97) and non-NE tumors (n=626) across all histologic grades and anatomic subsites of the head and neck. INSM1 was positive in all types of head and neck NE tumors evaluated here (99.0{\%} sensitivity), including middle ear adenoma, pituitary adenoma, paraganglioma, medullary thyroid carcinoma, olfactory neuroblastoma, small cell carcinoma, large cell NE carcinoma, and sinonasal teratocarcinosarcoma. Notably, it was positive in the vast majority of high-grade NE malignancies (95.8{\%} sensitivity). INSM1 also was negative in almost all non-NE tumors (97.6{\%} specificity) with the highest rates of reactivity in alveolar rhabdomyosarcoma and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (SMARCB1)-deficient sinonasal carcinoma. These findings confirm that INSM1 may be used as a standalone first-line marker of NE differentiation for tumors of the head and neck.",
keywords = "head and neck tumors, immunohistochemistry, INSM1, neuroendocrine tumors, surgical pathology",
author = "Rooper, {Lisa M.} and Bishop, {Justin A.} and Westra, {William H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/PAS.0000000000001037",
language = "English (US)",
volume = "42",
pages = "665--671",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors

AU - Rooper, Lisa M.

AU - Bishop, Justin A.

AU - Westra, William H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. We performed INSM1 immunohistochemistry on NE tumors (n=97) and non-NE tumors (n=626) across all histologic grades and anatomic subsites of the head and neck. INSM1 was positive in all types of head and neck NE tumors evaluated here (99.0% sensitivity), including middle ear adenoma, pituitary adenoma, paraganglioma, medullary thyroid carcinoma, olfactory neuroblastoma, small cell carcinoma, large cell NE carcinoma, and sinonasal teratocarcinosarcoma. Notably, it was positive in the vast majority of high-grade NE malignancies (95.8% sensitivity). INSM1 also was negative in almost all non-NE tumors (97.6% specificity) with the highest rates of reactivity in alveolar rhabdomyosarcoma and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (SMARCB1)-deficient sinonasal carcinoma. These findings confirm that INSM1 may be used as a standalone first-line marker of NE differentiation for tumors of the head and neck.

AB - The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. We performed INSM1 immunohistochemistry on NE tumors (n=97) and non-NE tumors (n=626) across all histologic grades and anatomic subsites of the head and neck. INSM1 was positive in all types of head and neck NE tumors evaluated here (99.0% sensitivity), including middle ear adenoma, pituitary adenoma, paraganglioma, medullary thyroid carcinoma, olfactory neuroblastoma, small cell carcinoma, large cell NE carcinoma, and sinonasal teratocarcinosarcoma. Notably, it was positive in the vast majority of high-grade NE malignancies (95.8% sensitivity). INSM1 also was negative in almost all non-NE tumors (97.6% specificity) with the highest rates of reactivity in alveolar rhabdomyosarcoma and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (SMARCB1)-deficient sinonasal carcinoma. These findings confirm that INSM1 may be used as a standalone first-line marker of NE differentiation for tumors of the head and neck.

KW - head and neck tumors

KW - immunohistochemistry

KW - INSM1

KW - neuroendocrine tumors

KW - surgical pathology

UR - http://www.scopus.com/inward/record.url?scp=85045695989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045695989&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000001037

DO - 10.1097/PAS.0000000000001037

M3 - Article

C2 - 29438167

AN - SCOPUS:85045695989

VL - 42

SP - 665

EP - 671

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -